Veracyte Statistics
Total Valuation
Veracyte has a market cap or net worth of $3.21 billion. The enterprise value is $2.88 billion.
| Market Cap | 3.21B |
| Enterprise Value | 2.88B |
Important Dates
The next estimated earnings date is Monday, February 23, 2026, after market close.
| Earnings Date | Feb 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Veracyte has 79.05 million shares outstanding. The number of shares has increased by 6.32% in one year.
| Current Share Class | 79.05M |
| Shares Outstanding | 79.05M |
| Shares Change (YoY) | +6.32% |
| Shares Change (QoQ) | +1.66% |
| Owned by Insiders (%) | 0.46% |
| Owned by Institutions (%) | 111.54% |
| Float | 78.65M |
Valuation Ratios
The trailing PE ratio is 106.65 and the forward PE ratio is 26.98.
| PE Ratio | 106.65 |
| Forward PE | 26.98 |
| PS Ratio | 6.41 |
| Forward PS | 5.73 |
| PB Ratio | 2.55 |
| P/TBV Ratio | 8.06 |
| P/FCF Ratio | 32.65 |
| P/OCF Ratio | 29.63 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 39.09, with an EV/FCF ratio of 29.34.
| EV / Earnings | 95.03 |
| EV / Sales | 5.82 |
| EV / EBITDA | 39.09 |
| EV / EBIT | 56.13 |
| EV / FCF | 29.34 |
Financial Position
The company has a current ratio of 6.23, with a Debt / Equity ratio of 0.03.
| Current Ratio | 6.23 |
| Quick Ratio | 5.74 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.48 |
| Debt / FCF | 0.41 |
| Interest Coverage | 51,328.00 |
Financial Efficiency
Return on equity (ROE) is 2.49% and return on invested capital (ROIC) is 5.33%.
| Return on Equity (ROE) | 2.49% |
| Return on Assets (ROA) | 2.43% |
| Return on Invested Capital (ROIC) | 5.33% |
| Return on Capital Employed (ROCE) | 3.96% |
| Weighted Average Cost of Capital (WACC) | 14.39% |
| Revenue Per Employee | $600,899 |
| Profits Per Employee | $36,792 |
| Employee Count | 824 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 7.15 |
Taxes
In the past 12 months, Veracyte has paid $693,000 in taxes.
| Income Tax | 693,000 |
| Effective Tax Rate | 2.23% |
Stock Price Statistics
The stock price has decreased by -7.40% in the last 52 weeks. The beta is 1.88, so Veracyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.88 |
| 52-Week Price Change | -7.40% |
| 50-Day Moving Average | 43.25 |
| 200-Day Moving Average | 33.61 |
| Relative Strength Index (RSI) | 41.63 |
| Average Volume (20 Days) | 731,649 |
Short Selling Information
The latest short interest is 4.99 million, so 6.31% of the outstanding shares have been sold short.
| Short Interest | 4.99M |
| Short Previous Month | 5.26M |
| Short % of Shares Out | 6.31% |
| Short % of Float | 6.34% |
| Short Ratio (days to cover) | 6.49 |
Income Statement
In the last 12 months, Veracyte had revenue of $495.14 million and earned $30.32 million in profits. Earnings per share was $0.38.
| Revenue | 495.14M |
| Gross Profit | 349.60M |
| Operating Income | 51.33M |
| Pretax Income | 31.01M |
| Net Income | 30.32M |
| EBITDA | 73.70M |
| EBIT | 51.33M |
| Earnings Per Share (EPS) | $0.38 |
Balance Sheet
The company has $366.43 million in cash and $40.45 million in debt, with a net cash position of $325.98 million or $4.12 per share.
| Cash & Cash Equivalents | 366.43M |
| Total Debt | 40.45M |
| Net Cash | 325.98M |
| Net Cash Per Share | $4.12 |
| Equity (Book Value) | 1.26B |
| Book Value Per Share | 15.91 |
| Working Capital | 377.07M |
Cash Flow
In the last 12 months, operating cash flow was $108.25 million and capital expenditures -$10.04 million, giving a free cash flow of $98.21 million.
| Operating Cash Flow | 108.25M |
| Capital Expenditures | -10.04M |
| Free Cash Flow | 98.21M |
| FCF Per Share | $1.24 |
Margins
Gross margin is 70.61%, with operating and profit margins of 10.37% and 6.12%.
| Gross Margin | 70.61% |
| Operating Margin | 10.37% |
| Pretax Margin | 6.26% |
| Profit Margin | 6.12% |
| EBITDA Margin | 14.88% |
| EBIT Margin | 10.37% |
| FCF Margin | 19.83% |
Dividends & Yields
Veracyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.32% |
| Shareholder Yield | -6.32% |
| Earnings Yield | 0.95% |
| FCF Yield | 3.06% |
Analyst Forecast
The average price target for Veracyte is $46.00, which is 13.38% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $46.00 |
| Price Target Difference | 13.38% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 10.97% |
| EPS Growth Forecast (5Y) | 41.55% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Veracyte has an Altman Z-Score of 14.54 and a Piotroski F-Score of 6.
| Altman Z-Score | 14.54 |
| Piotroski F-Score | 6 |